Vigor and the LDR in Parkinson Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

February 12, 2020

Primary Completion Date

April 25, 2024

Study Completion Date

April 25, 2024

Conditions
Parkinson Disease
Interventions
DRUG

carbidopa/levodopa, as prescribed by treating physician

"There will be 4 measurement states:~at baseline prior to chronic treatment initiation (OFF-No LDR); at baseline after a standard, acute oral dose (25/250 carbidopa/L-dopa), referenced in the protocol, but prescribed and provided by their prescribing physician as standard of care initial dosage (ON-No LDR); 2 months after initiation of chronic, stable L-dopa treatment (amounts and sequences as prescribed by treating physicians) but with no L-dopa for 10-12 hours prior to evaluation (Practical OFF- LDR); and after resuming subjects' usual physician-prescribed L-dopa dose (ON-LDR)."

Trial Locations (1)

48109

University of Michigan, Ann Arbor

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

University of Michigan

OTHER

NCT04821830 - Vigor and the LDR in Parkinson Disease | Biotech Hunter | Biotech Hunter